Autologous Stem Cell Transplant (ASCT)
Treatment for Hodgkin Lymphoma
Typical Dosage: High-dose chemotherapy (e.g., BEAM regimen) followed by autologous stem cell infusion
Effectiveness
75%
Safety Score
20%
Clinical Trials
117
Participants
10K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
20
DangerousModerateSafe
Treatment Details
Dosage Range
High-dose chemotherapy (e.g., BEAM regimen) followed by autologous stem cell infusion
Time to Effect
Engraftment in 2-4 weeks, recovery 3-6 months
Treatment Duration
Hospitalization 3-4 weeks, full recovery 6-12 months
Evidence Quality
HIGHConfidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$10,000
Monitoring:$15,000
Side Effect Mgmt:$20,000
Total Annual:$195,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
MODERATEQALYs Gained
5
Outcome-Based Costs
Cost per Responder
$325,000
Cost per Remission
$487,500
Autologous Stem Cell Transplant (ASCT) Outcomes
for Hodgkin Lymphoma
Efficacy Outcomes
Overall Effectiveness
+75%
Response Rate
+60%
Remission Rate
+40%
Common Side Effects
Severe Myelosuppression
+100%
Mucositis
+85%
Infection
+60%
Fatigue
+90%
Infertility
+70%
Secondary Malignancies
+5%
Active Clinical Trials
12 active trials recruiting for Autologous Stem Cell Transplant (ASCT) in Hodgkin Lymphoma
CAR-T Following ASCT for Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (R/R B-NHL) With High-Risk Prognostic Factors
NCT06365671RECRUITINGPHASE2
16 participants
INTERVENTIONAL
Shanghai, China
Started: Apr 16, 2024
Allo-HSCT Vs. Auto-HSCT for PTCL Patients With PR After First-line Systemic Therapy : A Prospective, Multicenter, Cohort Study-(T-START-PR)
NCT07253129RECRUITING
88 participants
OBSERVATIONAL
Shanghai, China
Started: Dec 31, 2025
MT2022-60: Ph 2 Study of Pembro+ BEAM With ASCT for Relapsed Hodgkin Lymphoma
NCT06377540RECRUITINGPHASE2
28 participants
INTERVENTIONAL
Minneapolis, United States
Started: Dec 4, 2024
CNS-Relapse Prevention in High-Risk Diffuse Large B-cell Lymphoma With Thiotepa-based Autologous Stem Cell Transplant
NCT06687772RECRUITINGPHASE2
36 participants
INTERVENTIONAL
St Louis, United States
Started: Jan 16, 2025
RWE of Brentuximab Vedotin Consolidation in Patients With RR HL Who Receive Salvage Chemotherapy and ASCT
NCT04776265RECRUITING
100 participants
OBSERVATIONAL
El Palomar, Argentina +14 more
Started: Jun 1, 2021
Venetoclax in Combination With BEAM Conditioning Regimen for ASCT in Non-Hodgkin Lymphoma
NCT03713580ACTIVE NOT RECRUITINGPHASE1
25 participants
INTERVENTIONAL
Cleveland, United States +1 more
Started: Mar 12, 2019
A Study of Brentuximab Vedotin in Adults With Hodgkin's Lymphoma
NCT05100056RECRUITING
70 participants
OBSERVATIONAL
Wroclaw, Poland +12 more
Started: Mar 8, 2022
Clinical Study of the Safety and Efficacy of ASCT Combined With CD7-CART in the Treatment of CD7+ TCL
NCT07106723RECRUITINGPHASE2
50 participants
INTERVENTIONAL
Tianjin, China
Started: Jun 1, 2025
Glofitamab Bridging ASCT for Patients With Relapsed or Refractory DLBCL
NCT06682130RECRUITINGPHASE2
40 participants
INTERVENTIONAL
Suzhou, China
Started: Nov 10, 2024
Bendamustine Combined With Chidamide and Lenalidomide for Relapsed and Refractory PTCL Patients
NCT07072221RECRUITINGNA
40 participants
INTERVENTIONAL
Suzhou, China
Started: Nov 1, 2024
Frontline of ASCT in High-risk DLBCL
NCT05831865RECRUITING
175 participants
OBSERVATIONAL
Beijing, China
Started: May 3, 2023
Transplantation After Complete Response In Patients With T-cell Lymphoma
NCT05444712RECRUITINGNA
204 participants
INTERVENTIONAL
Amiens, France +47 more
Started: Aug 1, 2022
Completed Clinical Trials
4 completed trials for Autologous Stem Cell Transplant (ASCT) in Hodgkin Lymphoma
The Efficacy of Salvage BGD With autoSCT Consolidation in Advanced Classical HL Patients Not Responding to ABVD
NCT03615664COMPLETEDPHASE2
115 participants
INTERVENTIONAL
Bydgoszcz, Poland +12 more
Started: Nov 6, 2017
Two Different Methods of Collecting Stem Cells For an Autologous Stem Cell Transplant in Treating Patients With Diffuse Large Cell Lymphoma
NCT00566228COMPLETEDPHASE3
122 participants
INTERVENTIONAL
Rochester, United States
Started: Dec 1, 2007
Rituximab After Autologous Stem Cell Transplant for Relapsed B-cell Non-Hodgkin's Lymphoma
NCT00225212COMPLETEDPHASE2
35 participants
INTERVENTIONAL
Stanford, United States
Started: Nov 1, 1997
Targeted Intensification With ZBEAM and Autologous Stem Cell Transplantation in Patients With High-grade B-Cell Lymphoma
NCT00689169COMPLETEDPHASE2
75 participants
INTERVENTIONAL
Paris, France
Started: Aug 1, 2007
Showing 20 of 118 total trials